Drug Delivery Deal Valuations
Executive Summary
In recent years, Big Pharma has increasingly begun to regard drug delivery as an important part of the drug development process, rather than merely an issue of prolonging the marketplace life of aging products, particularly when it comes to the delivery of large molecules. Average deal valuations in drug delivery have jumped accordingly.